HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine intratumoral concentration of kinase inhibitors
upon 2 weeks of treatment in tumor tissue (in the brain) of patients with high-grade gliomas
(HGG).
Phase:
N/A
Details
Lead Sponsor:
VU University Medical Center
Treatments:
Erlotinib Hydrochloride Protein Kinase Inhibitors Sunitinib